DNAJA1 and cancer: Collectively, these data strongly demonstrate that the DNAJA1–mutp53 complex is a critical target for mutp53-driven cancer and GY1-22 is a novel small molecule inhibitor against the DNAJA1–mutp53R175H complex with low toxicity.